Let Your Immune System
Treat Your Cancer

Denvax Testimonial

Google Rating

Nisha Khan



Very improvement and doctor is very nice and polite…

Bhupendra Adhikari



When i was taking chemotherapy i was not feeling well but after taking dendritic cell therapy i felt better and my pet scan report also came negative.

Rakesh Insurance Cons.



Satisfactory Treatment, Petient is Fit and fine after taking Danvax treatment.

anuj kumar



I am feeling better after Denvax treatment immunotherapy Maine bahut sara hospital visit kiya usne bahut bada problem batay lekin jab mai Dr jamal ke clinic pr aaya ...maine apna treatment krwane ke baad bahut achha lg rha h...Thanks soo much Dr jamal a khan

sana khan



The treatment offered here is the best overall India. Staff is really cooperative and polite. I have really seen miracles happening over here at The Danvax.

Zaid Irfan



I am feeling excellent after treatment from denvex.My health has improved and I can feel the difference in my body.

Dev Narayan Mandal



I am feeling much better after the treatment from Denvax clinic.I am Hodgkin Lymphoma (Blood cancer ) patient of 4 th stage.This Immunotherapy treatement is much comfortable easier and safe treatment .My health has improved and I can feel the actual difference in my body.

Ts Chahal



I am feeling very good after Denvax treatment thanks for Dr Jamal Sir.

Sarojine Wali



My mother Chuni Peer was diagnosed with cancer left breast in march 2021. She is feeling excellent after treatment from denvex. Her health has improved alot. Thanks to Dr.Jamal Sir and his entire team. The doctor and the staff are polite and humble. She is feeling a lot of difference in her body after the treatment. I here by advice everyone suffering from this deadly decease to try this treatment. This immunotherapy treatment is much comfortable and safe treatment. I once again thank every member of denvex clinic for their hospitality.

Arun Sharma



I was diagnosed with Brain tumor (GBM). Along with Radio and chemotherapy this Denvax therapy worked nicely. Currently I m under Denvax treatment for more than 1 year...and I m feeling well enough..The treatment will follow for 3 more months with chemotherapy provided by Dr Jamal Khan..The Doctor and the staff are pollite and humble at every step. Atlast I m telling everyone that you should try this treatment hence it is effective according to my experience.

Rinku Devi



Denvax clinic is Owsam.Dr Jamal A khan and Dr Sharmin yaqin more experience doctor in field of immunotherapy treatment process. Thanks for Dr jamal and Dr Sharmin and Thanq also for Rahul Tak and Taquir Sir He is more support for insurance process.

Pavan Kumar



My Name is Pavan and I am from Delhi. My Cancer was diagnosed in March 2021 in lungs. I start taking medicine from Denvax. After the 12 doses of Immunotherapy and third test of PETCT. finally I am out of cancer, and back to my normal life. Thanks to Mr. Jamal Sir and his team for gave me new life. Thanks to Rohit sir, Raman Sir and Marry. I strongly recommended Denvex for this type of treatment.

Mukesh Gupta



Very well experienced and managed Doctors at Service for patients .place is Neat and Clean .Good Housekeeping very helpful and pleasant Reception... Thanks.

Mashirul Haque



I am filling whel after the treatment thank Dr Jamal Khan sir.

Ranvir Sain



Hello I am Ranveer Singh I would like to inform all of you that I was undergoing treatment for my tongue cancer from last 1 year under the leadership of Gen Max Clinic Dr Ek Jamal ji, I am now 90 percent relaxed. I can eat and speak, it is very relaxing, I would advise all of you that once you hit the Denwax clinic and consult and you will definitely benefit from meeting Dr. Jamal Sahab Thank you Jai Hind Jai Bharat.

IMRAN SIDDIQUE



Hamne 6 dose k bad cancer ko mat diya Denvax dose lene k bad.

Nazar Mohammed



Mai Gonda ka rehne wala hu, Mai doc sahab ka bahut aabahari hu ki mai Sahab ka ilaj liya aur sirf 3 dose me hi mujhe aaram mil gaya aj. Allah Doctor sahab ko khub Barakat de ki mere jese aur marizo ko thik kar sake.

Abdul Khaleel



Very Good treatment for cancer patients by denvax . My father was diagnosed with prostate cancer . He was completely on bed ,but by the help of denvax team he is able to recover efficiently .we took treatment of 6 doses which was recommended and supervised by Dr. Jillela Rakesh Reddy. He was quiet patience and helpful throughout the process . Abdul khaleel Inquired about the patient recovery and guided the treatment in a timely manner, Abdul kamal was very helpful for whole process. Special thanks to Dr. jamal sir Dr. jillela Rakesh sir, and Denvax team.

Denvax Success Stories

• NON HODGKINS LYMPHOMA

  A 46-year-old male was operated for mediastinal tumor in 2010. It was diagnosed as T-cell lymphoma (Lymphoblastic Lymphoma). He started his treatment with chemotherapy. Each time he had to be admitted for managing the complications of chemotherapy. He was losing weight and appetite and having erosions of mucosal membrane. He required G-CSF injections along with antibiotics and lots of IV fluids to maintain his cell counts and nutrition. He was unable to tolerate 4th dose of chemotherapy when he consulted his oncologist to combine chemotherapy with dendritic cell therapy. During the course of conventional treatment, he received mediastinal radiation also for 4 weeks.  The oncologist accepted the protocol and the chemotherapy was combined with DENVAX cell therapy doses that concluded in six months (from November 2010 to April 2011).  

  With this combined approach he stopped developing the post-chemotherapy complication. The patient suffered no chemo-related adverse effects contrary to the earlier findings. He has improved in performance status and is working in his office without taking a day-off from work. He is having regular follow ups and is free of disease as confirmed by his PET-CT in January 2011.

• PANCREATIC CANCER TREATMENT

  Ms. ArunaTyagi, a 44-year-old patient of cholangiocarcinoma (gallbladder duct) treated by Dr. Jamal A. Khan by dendritic cell therapy, is cancer-free for the last five years. Ms. Tyagi had primary cancer in common bile duct, pancreas and duodenum. She was operated upon by Whipple's procedure in May 2006 and completed her chemotherapy and radiation, but the success was short lived. After 9 months she developed a swelling in abdominal wall (secondary metastsis). The surgeon took a second chance and she was again operated for abdominal metastasis. She was offered second line chemotherapy by her treating physician but she refused knowing it would not give her long term benefits. She came to know of Dr. Jamal A. Khan, cancer immunotherapist, pioneer of Dendritic cell therapy in India. Dr. Khan MBBS, MD who has treated over a thousand patients till date, discussed the cancer treatment plan with her. She was constantly monitored by serum marker tests and ultrasound exams. Gradually, the DENVAX therapy was given at increasing intervals. In August 2009, she was subjected to PET-CT examination and found to be completely free of disease with no active lesions found. 
  
  She continues to receive Denvax Therapy from Dr. Jamal A. Khan and is cancer-free, till date.

  Disclaimer: It is the OTPL’s policy never to disclose patient identity. This is an isolated case where we are disclosing the patient's identity. This information is shared in consent with Mrs. ArunaTyagi. It has also been covered in the magazine 'The Week' published from India dated 11 August, 2012.

• RENAL CANCER

  A 60-year-old female presented with metastatic clear cell carcinoma of kidney in December 2007. Her right kidney was excised and subjected to histopathology examination. It revealed pathological stage TNM- pT3 N1 M1. Her complaints were pain in abdomen and frequent urination. She presented with weight loss and anemia.
  She was given the option of DENVAX, dendritic cell-based immunotherapy. She received five doses at monthly interval. In three doses, her complaints began to resolve and was back to her normal self in five doses. Intermittently, she continued to receive DENVAX therapy.

  She was again evaluated in March 2011 for routine check up and was further advised to received additional DC therapies. Her reports indicate no active disease. Overall her health is good and she does all her normal activities without any assistance.

  She is completing 4 years of her quality life without receiving chemotherapy, monoclonal antibodies or interferons and is maintained on dendritic cell therapy.

• CANCER URINARY BLADDER

  An elderly male suffering from cancer of the urinary bladder (Transitional Cell Carcinoma) received Denvax therapy. He developed the disease in 2012 that was surgically removed. Post-surgery he opted for Denvax therapy. The referral came from his daughter who is a leading pathologist in Mumbai. During the first three months of therapy he additionally received BCG infusions into the urinary bladder given by his surgeon. Unfortunately, the disease relapsed in four months and he had to undergo second surgery to clear off the lesion. They were now having options to take chemotherapy although expected success was very little. The surgeon asked them to consider taking out urinary bladder completely but patient refused due to the poor quality of life he would lead. We suggested considering exclusive Dendritic cell therapy as BCG had failed to check the disease before moving to next step. It is known that the BCG treatment creates inflammatory response and serves as bait for immune cells to come and take control of cancer cells. The inflammatory response probably disturbed the T-cell based protection that we were going to get with Dendritic cells. The patient agreed and we gave him another set of six doses of Denvax. He was re-examined and no new growth of tumor was detected. He continues to receive Denvax at three-months interval. It is almost three years of disease-free period now. He plays golf five days-a week and drives his car at the age of 76 years.

• LIVER CANCER

  A young female consulted me in late 2014. She had a history of HCC (Hepatocellular carcinoma) with Hepatitis B positive status, with resection performed in early 2014. Gradually she progressed with disease. When she came to our clinic she had weakness and lethargy. Her PET-CT indicated disease in the liver and lungs. Her lab parameters were deranged but serum bilirubin was within normal limits. She was put on Denvax, dendritic cell therapy, and within three months of therapy she started showing signs of improvement. Her latest PET-CT done this month has shown complete resolution of the disease. Additionally, her hepatitis B test has become negative. Nothing of this sort has ever been reported in the medical literature.

• KIDNEY CANCER

  A dynamic, middle-aged male diagnosed of metastatic RCC (Renal cell carcinoma) and operated in 2012, developed widespread metastasis by 2013. He was treated in one of the leading hospitals in Gurgaon. He was taking monoclonal antibody (mab) designed for RCC but to no avail. He consulted and opted for additional (adjuvant) Dendritic cell therapy. We gave him the first dose in January 2014. The mab was gradually reduced to half and subsequently to quarter of the standard dose. He started gaining weight and cleared off of all his lesions in the body. His PET CT indicated complete resolution of the disease. He is on dendritic cell therapy maintenance therapy at monthly intervals. He travels widely not only between cities but countries due to his professional commitments. He can afford that as his health is perfectly normal and has no complaints of whatsoever type he used to have earlier.  His lab parameters are also normal. He is evaluated in August 2015

• OVARIAN CANCER TREATMENT

  A 58-year-old lady was diagnosed of cancer ovary in June 2004. Her CA 125 antigen marker was positive and in the range of 10,000 units. She was operated upon and given six cycles of chemotherapy. She recovered from her disease and her marker was also within normal range.  After one year, the CA 125 began rising and she presented to us with an increased titre of 400 units. There were signs of recurrence, and she opted for DC (DENVAX) therapy in June 2005. She has completed three years of receiving DENVAX. She is free of disease, proven both clinically and by radiological examinations. Her CA 125 marker is also stable for the last three years.We have done series of ovarian cancer patients and the presentation is available in publications section of our webpages.

Denvax Success Stories

• NON HODGKINS LYMPHOMA

  A 46-year-old male was operated for mediastinal tumor in 2010. It was diagnosed as T-cell lymphoma (Lymphoblastic Lymphoma). He started his treatment with chemotherapy. Each time he had to be admitted for managing the complications of chemotherapy. He was losing weight and appetite and having erosions of mucosal membrane. He required G-CSF injections along with antibiotics and lots of IV fluids to maintain his cell counts and nutrition. He was unable to tolerate 4th dose of chemotherapy when he consulted his oncologist to combine chemotherapy with dendritic cell therapy. During the course of conventional treatment, he received mediastinal radiation also for 4 weeks.  The oncologist accepted the protocol and the chemotherapy was combined with DENVAX cell therapy doses that concluded in six months (from November 2010 to April 2011).  

  With this combined approach he stopped developing the post-chemotherapy complication. The patient suffered no chemo-related adverse effects contrary to the earlier findings. He has improved in performance status and is working in his office without taking a day-off from work. He is having regular follow ups and is free of disease as confirmed by his PET-CT in January 2011.

• PANCREATIC CANCER TREATMENT

  Ms. ArunaTyagi, a 44-year-old patient of cholangiocarcinoma (gallbladder duct) treated by Dr. Jamal A. Khan by dendritic cell therapy, is cancer-free for the last five years. Ms. Tyagi had primary cancer in common bile duct, pancreas and duodenum. She was operated upon by Whipple's procedure in May 2006 and completed her chemotherapy and radiation, but the success was short lived. After 9 months she developed a swelling in abdominal wall (secondary metastsis). The surgeon took a second chance and she was again operated for abdominal metastasis. She was offered second line chemotherapy by her treating physician but she refused knowing it would not give her long term benefits. She came to know of Dr. Jamal A. Khan, cancer immunotherapist, pioneer of Dendritic cell therapy in India. Dr. Khan MBBS, MD who has treated over a thousand patients till date, discussed the cancer treatment plan with her. She was constantly monitored by serum marker tests and ultrasound exams. Gradually, the DENVAX therapy was given at increasing intervals. In August 2009, she was subjected to PET-CT examination and found to be completely free of disease with no active lesions found. 
  
  She continues to receive Denvax Therapy from Dr. Jamal A. Khan and is cancer-free, till date.

  Disclaimer: It is the OTPL’s policy never to disclose patient identity. This is an isolated case where we are disclosing the patient's identity. This information is shared in consent with Mrs. ArunaTyagi. It has also been covered in the magazine 'The Week' published from India dated 11 August, 2012.

• RENAL CANCER

  A 60-year-old female presented with metastatic clear cell carcinoma of kidney in December 2007. Her right kidney was excised and subjected to histopathology examination. It revealed pathological stage TNM- pT3 N1 M1. Her complaints were pain in abdomen and frequent urination. She presented with weight loss and anemia.
  She was given the option of DENVAX, dendritic cell-based immunotherapy. She received five doses at monthly interval. In three doses, her complaints began to resolve and was back to her normal self in five doses. Intermittently, she continued to receive DENVAX therapy.

  She was again evaluated in March 2011 for routine check up and was further advised to received additional DC therapies. Her reports indicate no active disease. Overall her health is good and she does all her normal activities without any assistance.

  She is completing 4 years of her quality life without receiving chemotherapy, monoclonal antibodies or interferons and is maintained on dendritic cell therapy.

• CANCER URINARY BLADDER

  An elderly male suffering from cancer of the urinary bladder (Transitional Cell Carcinoma) received Denvax therapy. He developed the disease in 2012 that was surgically removed. Post-surgery he opted for Denvax therapy. The referral came from his daughter who is a leading pathologist in Mumbai. During the first three months of therapy he additionally received BCG infusions into the urinary bladder given by his surgeon. Unfortunately, the disease relapsed in four months and he had to undergo second surgery to clear off the lesion. They were now having options to take chemotherapy although expected success was very little. The surgeon asked them to consider taking out urinary bladder completely but patient refused due to the poor quality of life he would lead. We suggested considering exclusive Dendritic cell therapy as BCG had failed to check the disease before moving to next step. It is known that the BCG treatment creates inflammatory response and serves as bait for immune cells to come and take control of cancer cells. The inflammatory response probably disturbed the T-cell based protection that we were going to get with Dendritic cells. The patient agreed and we gave him another set of six doses of Denvax. He was re-examined and no new growth of tumor was detected. He continues to receive Denvax at three-months interval. It is almost three years of disease-free period now. He plays golf five days-a week and drives his car at the age of 76 years.

• LIVER CANCER

  A young female consulted me in late 2014. She had a history of HCC (Hepatocellular carcinoma) with Hepatitis B positive status, with resection performed in early 2014. Gradually she progressed with disease. When she came to our clinic she had weakness and lethargy. Her PET-CT indicated disease in the liver and lungs. Her lab parameters were deranged but serum bilirubin was within normal limits. She was put on Denvax, dendritic cell therapy, and within three months of therapy she started showing signs of improvement. Her latest PET-CT done this month has shown complete resolution of the disease. Additionally, her hepatitis B test has become negative. Nothing of this sort has ever been reported in the medical literature.

• KIDNEY CANCER

  A dynamic, middle-aged male diagnosed of metastatic RCC (Renal cell carcinoma) and operated in 2012, developed widespread metastasis by 2013. He was treated in one of the leading hospitals in Gurgaon. He was taking monoclonal antibody (mab) designed for RCC but to no avail. He consulted and opted for additional (adjuvant) Dendritic cell therapy. We gave him the first dose in January 2014. The mab was gradually reduced to half and subsequently to quarter of the standard dose. He started gaining weight and cleared off of all his lesions in the body. His PET CT indicated complete resolution of the disease. He is on dendritic cell therapy maintenance therapy at monthly intervals. He travels widely not only between cities but countries due to his professional commitments. He can afford that as his health is perfectly normal and has no complaints of whatsoever type he used to have earlier.  His lab parameters are also normal. He is evaluated in August 2015

• OVARIAN CANCER TREATMENT

  A 58-year-old lady was diagnosed of cancer ovary in June 2004. Her CA 125 antigen marker was positive and in the range of 10,000 units. She was operated upon and given six cycles of chemotherapy. She recovered from her disease and her marker was also within normal range.  After one year, the CA 125 began rising and she presented to us with an increased titre of 400 units. There were signs of recurrence, and she opted for DC (DENVAX) therapy in June 2005. She has completed three years of receiving DENVAX. She is free of disease, proven both clinically and by radiological examinations. Her CA 125 marker is also stable for the last three years.We have done series of ovarian cancer patients and the presentation is available in publications section of our webpages.